We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+2.22%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$563M
AUM Growth
+$168M
Cap. Flow
+$106M
Cap. Flow %
18.87%
Top 10 Hldgs %
78.85%
Holding
47
New
15
Increased
6
Reduced
2
Closed
11
Avg Time Held Equity + Options
2.2 quarters
Top 10 Avg Time Held Equity + Options
2.4 quarters
Top 20 Avg Time Held Equity + Options
2.2 quarters
Avg Time Held Equity only
2.4 quarters
Top 10 Avg Time Held Equity only
2.6 quarters
Top 20 Avg Time Held Equity only
2.5 quarters

Top Buys

Rank Stock Value
1
KYNB icon
Kyntra Bio
KYNB
+$43M
2
FBRX icon
Forte Biosciences
FBRX
+$22.5M
3
SGMO icon
SANGAMO THERAPEUTICS INC
SGMO
+$16.5M
4
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$14.7M
5
EDIT icon
Editas Medicine
EDIT
+$12.9M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$13.3M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$8.94M
3
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$5.68M
4
XNCR icon
Xencor
XNCR
+$5.62M
5
KURA icon
Kura Oncology
KURA
+$5.26M

Sector Composition

Rank Sector Weight
1 Healthcare 76.97%
2 Miscellaneous 23.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ALXN
1
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$78.2M 13.89%
+569,500
New +$66.3M
2017 Q2
0 quarters
IRWD icon
2
Ironwood Pharmaceuticals
IRWD
$593M
$70.9M 12.58%
4,481,840
+1,012,655
+29% +$14.7M
2015 Q4
6 quarters
ASMB icon
3
Assembly Biosciences
ASMB
$414M
$60.8M 10.79%
245,264
– –
2014 Q4
10 quarters
KYNB icon
4
Kyntra Bio
KYNB
$23.8M
$51.2M 9.09%
63,418
+61,738
+3,675% +$43M
2014 Q4
10 quarters
LKFT icon
5
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$44.3M 7.86%
578,505
+27,464
+5% +$2.31M
2015 Q4
6 quarters
ASND icon
6
Ascendis Pharma A/S
ASND
$14.7B
$41.2M 7.31%
1,482,600
+456,900
+45% +$12.1M
2016 Q3
3 quarters
GILD icon
7
CALL
Gilead Sciences
GILD
$183B
$38M 6.75%
500,000
– –
2017 Q1
1 quarter
SGMO icon
8
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$22.6M 4.01%
+2,568,119
New +$16.5M
2017 Q2
0 quarters
KURA icon
9
Kura Oncology
KURA
$874M
$18.9M 3.36%
2,033,622
-578,284
-22% -$5.26M
2015 Q4
6 quarters
FBRX icon
10
DELISTED
Forte Biosciences
FBRX
$18.1M 3.21%
+4,006
New +$22.5M
2017 Q2
0 quarters
CTMX icon
11
CytomX Therapeutics
CTMX
$508M
$12.3M 2.19%
794,969
– –
2017 Q1
1 quarter
EDIT icon
12
Editas Medicine
EDIT
$375M
$12M 2.14%
+717,107
New +$12.9M
2017 Q2
0 quarters
CASC
13
DELISTED
Cascadian Therapeutics, Inc.
CASC
$11.1M 1.98%
3,000,000
– –
2017 Q1
1 quarter
CRVS icon
14
Corvus Pharmaceuticals
CRVS
$792M
$9.74M 1.73%
+805,000
New +$8.59M
2017 Q2
0 quarters
VRTX icon
15
CALL
Vertex Pharmaceuticals
VRTX
$123B
$9.11M 1.62%
+60,000
New +$7.22M
2017 Q2
0 quarters
FATE icon
16
Fate Therapeutics
FATE
$240M
$8.22M 1.46%
2,537,026
– –
2017 Q1
1 quarter
ATYR icon
17
aTyr Pharma
ATYR
$19.7M
$7.79M 1.38%
163,761
– –
2016 Q4
2 quarters
TPST icon
18
Tempest Therapeutics
TPST
$11.5M
$5.48M 0.97%
1,201
– –
2017 Q1
1 quarter
ACRS icon
19
Aclaris Therapeutics
ACRS
$511M
$5.03M 0.89%
185,472
-487,628
-72% -$13.3M
2016 Q4
2 quarters
KIN
20
DELISTED
Kindred Biosciences, Inc.
KIN
$4.69M 0.83%
544,880
– –
2014 Q4
10 quarters
TTPH
21
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$4.52M 0.8%
+31,670
New +$4.89M
2017 Q2
0 quarters
EDIT icon
22
CALL
Editas Medicine
EDIT
$375M
$4.32M 0.77%
+255,000
New +$4.6M
2017 Q2
0 quarters
RGLS icon
23
DELISTED
Regulus Therapeutics
RGLS
$3.66M 0.65%
30,910
+18,327
+146% +$3.06M
2017 Q1
1 quarter
ACHN
24
DELISTED
Achillion Pharmaceuticals
ACHN
$3.41M 0.61%
+742,835
New +$2.99M
2017 Q2
0 quarters
NBRV
25
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.77M 0.49%
1,059
– –
2015 Q3
7 quarters
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2017 Portfolio in Review

As of Q2 2017, EcoR1 Capital held 47 positions worth $563M, up 42% from $396M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

EcoR1 Capital deployed $106M of net new capital in Q2 2017, opening 15 new positions and adding to 6 existing holdings. Its largest new stake was Forte Biosciences: 4,006 shares worth $18.1M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 86% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $13.3M trimmed.

  • EcoR1 Capital's largest Q2 2017 buy was Forte Biosciences: 4,006 shares worth $18.1M.
  • EcoR1 Capital added most to Kyntra Bio in Q2 2017, an estimated $43M increase.
  • EcoR1 Capital's biggest Q2 2017 reduction was Aclaris Therapeutics, cutting an estimated $13.3M.
  • EcoR1 Capital fully exited Atara Biotherapeutics in Q2 2017, selling an estimated $8.94M.
  • EcoR1 Capital's ten largest holdings make up 79% of its $563M portfolio in Q2 2017.
  • EcoR1 Capital opened 15 new positions and closed 11 in Q2 2017.
  • EcoR1 Capital's portfolio value rose 42% quarter-over-quarter to $563M.

Based on EcoR1 Capital's 13F filing for Q2 2017, filed 14 Aug 2017.